Free tool
FAERS Monitor: Ellence
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050778 or its brand name (Ellence, Epirubicin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
6,498
Serious
6,286
97% of reports
Hospitalization
2,517
Death reported
478
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- myelosuppression726
- nausea553
- white blood cell count decreased493
- alopecia459
- vomiting419
- febrile neutropenia371
- pyrexia339
- asthenia326
- neutropenia278
- hepatic function abnormal274
- neutrophil count decreased272
- off label use235
- diarrhoea221
- decreased appetite192
- fatigue188
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 33 |
| 2005 | 14 |
| 2006 | 20 |
| 2007 | 62 |
| 2008 | 67 |
| 2009 | 50 |
| 2010 | 137 |
| 2011 | 269 |
| 2012 | 334 |
| 2013 | 135 |
| 2014 | 120 |
| 2015 | 185 |
| 2016 | 169 |
| 2017 | 153 |
| 2018 | 361 |
| 2019 | 337 |
| 2020 | 290 |
| 2021 | 388 |
| 2022 | 709 |
| 2023 | 722 |
| 2024 | 838 |
| 2025 | 636 |
| 2026 | 469 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,661 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 726 | 66.6 | 62.1 | 45,955 |
| hepatic function abnormalSignal | 274 | 23.9 | 21.3 | 5,965 |
| neutrophil count decreasedSignal | 272 | 21.7 | 19.3 | 5,336 |
| febrile neutropeniaSignal | 371 | 18.2 | 16.5 | 5,998 |
| white blood cell count decreasedSignal | 493 | 14.8 | 13.6 | 6,326 |
| alopeciaSignal | 459 | 7.6 | 6.9 | 2,634 |
| neutropeniaSignal | 278 | 6.6 | 5.9 | 1,329 |
| pyrexiaSignal | 339 | 3.2 | 2.9 | 510 |
| vomitingSignal | 419 | 2.9 | 2.6 | 526 |
| astheniaSignal | 326 | 2.8 | 2.5 | 384 |
| decreased appetiteSignal | 192 | 2.7 | 2.3 | 202 |
| nauseaSignal | 553 | 2.3 | 2.1 | 403 |
| diarrhoea | 221 | 1.1 | 1.0 | 2 |
| off label use | 235 | 0.9 | 0.8 | 5 |
| fatigue | 188 | 0.8 | 0.7 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.